Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded
Pregnant women are excluded from this research; the male partner should use a condom
Pregnant women are excluded from this study; breastfeeding women are also excluded
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study as the proposed treatment has not been well studied in pregnant subjects.
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study; breastfeeding women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded
Pregnant patients will be excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women and women of childbearing potential are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded
Pregnant women are excluded from this study
Pregnant women are excluded from enrollment on this study
Excluded patient groups:\r\n* Pregnant women are excluded from this study; breastfeeding women will not be included in the study\r\n* Human immunodeficiency virus (HIV)-seropositive patients are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Patient is a pregnant woman (pregnant women are excluded from this study)
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Pregnant women are excluded from this study
Men are excluded from this study
Pregnant women will be excluded
YBCS: Women who are pregnant at recruitment will be excluded from this study; however, during the course of follow up, women who become pregnant will be included
Pregnant women are excluded from this study
Pregnant patients will be excluded
All others will be excluded
Pregnant patients-excluded by history
Pregnant women are naturally excluded given condition of cisplatin therapy
Pregnant women are excluded from this study
Men are excluded from this study
Pregnant women are excluded
Pregnant women are excluded from participating in this study
Pregnancy; (pregnant women will be excluded from this study)
Pregnant women are excluded from this study
Pregnant women are excluded
Pregnant women are excluded from this study
Pregnant women are excluded from this study; women who are breastfeeding are also excluded from this study
Pregnant women are excluded
Pregnant women are excluded from this study
Patients who are pregnant are excluded
Pregnant patients are to be excluded
Women who are pregnant will be excluded from the trial
Pregnant patients are excluded
Must not be breastfeeding/lactating.
Breastfeeding should be discontinued
Lactating or breastfeeding women are excluded, breastfeeding should be discontinued prior to being treated with AZD1775; these potential risks may also apply to other agents used in this study
Breastfeeding
Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral THU-Dec
Women who are breastfeeding and who are unwilling to stop breastfeeding prior to study entry
Inability or refusal to practice effective contraception during therapy or the presence of pregnancy or active breastfeeding; pregnant or breastfeeding women will be excluded from participation in this trial
Female patients who are breastfeeding; breastfeeding should be discontinued if the mother is treated with Pexa-Vec
Female patients who are pregnant or breastfeeding; breastfeeding should be discontinued
Not breastfeeding
Breastfeeding patients are ineligible
Women must not be pregnant or breastfeeding; breastfeeding must be discontinued or the subject is not eligible for the study
PHASE II: Women must not be pregnant or breastfeeding; breastfeeding must be discontinued or the subject is not eligible for the study
Breastfeeding should be discontinued
Breastfeeding
Breastfeeding
Pregnant or breastfeeding; breastfeeding may not resume for 14 days after the last dose of pazopanib
Not breastfeeding
Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral tetrahydrouridine- decitabine [THU-Dec])
Participants who are breastfeeding are excluded
They are not breastfeeding;
Currently breastfeeding.
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with denosumab; there is no minimum amount of time since pregnancy/breastfeeding required before enrolling into the study; however, the date of delivery, pregnancy termination, or weaning from breastfeeding will be documented on case report forms; female subjects of child bearing potential and not willing to use, in combination with her partner, highly effective contraception during treatment will be excluded
Current breastfeeding
Breastfeeding
No breastfeeding
Breastfeeding
Participants who are breastfeeding are excluded
Breastfeeding
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with chemoembolic agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either agent, and for 30 days after discontinuation of therapy
Pregnant women are excluded from this study; breastfeeding must be discontinued while the mother is taking study drug and for at least 28 days after discontinuation of study drug
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant or lactating women are excluded from this study; breastfeeding must be discontinued for the duration of study participation and for 56 days after the last dose of the study agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this study agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Breastfeeding must be discontinued for the duration of study participation and for one month after the last dose of the study agent if the mother is treated with 9cUAB30
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
CELL PROCUREMENT: Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use if the milk is collected while the mother is being treated on study)
LYMPHODEPLETION: Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use if the milk is collected while the mother is being treated on study)
Pregnant or breastfeeding (Note: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or breastfeeding, or plan to be pregnant within projected duration of the trial, starting with the screening visit through 4 months after the last dose of mirvetuximab soravtansine (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiation
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either therapy
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab; (Note: pregnancy testing should be performed within 14 days prior to randomization according to institutional standards for women of childbearing potential)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumab
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is treated with taselisib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with tremelimumab and MEDI3617
Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with ruxolitinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with afatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide or pomalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ficlatuzumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT2385
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bavituximab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ramucirumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with eribulin; these potential risks may also apply to other agents used in this study.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PLX3397 and sirolimus
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ponatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 and paclitaxel
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with talazoparib (BMN 673)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with everolimus
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with natalizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with the study drugs
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with WDVAX
Persons who are pregnant are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab or nivolumab; a negative serum pregnancy test is required prior to study entry
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BVD523
Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry\r\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab, gemcitabine, and oxaliplatin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with abemaciclib; a negative serum pregnancy test is required for women of childbearing potential prior to study entry
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated
EXPANDED ACCESS COHORT: Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with merestinib and LY2874455
Active pregnancy or breast-feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gefitinib or osimertinib agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LY3022855; these potential risks may also apply to the other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970) and/or gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 (onalespib)
Pregnant or breastfeeding women; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gemcitabine or IMGN853
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IMA950-poly-ICLC vaccine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with merestinib
Breastfeeding should be discontinued if the mother wishes to participate in this study
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GBM6-AD-poly vaccine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation
Pregnant or nursing patients will be excluded from the study; breastfeeding should be discontinued if the mother is treated with sunitinib or everolimus
Patients who are pregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with selinexor
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiopharmaceutical agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PTX-200; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with carfilzomib/lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Combotox
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pyrimethamine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with rucaparib and mirvetuximab soravtansine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LMB-100 + SEL-110
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M7824
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC201
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC201
COHORT 3: ENDOMETRIAL CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC201
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with clofarabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and navitoclax
Pregnant and/or breastfeeding women or unable to maintain use of contraception while on study and for 30 days after the last dose of study drug; breastfeeding should be discontinued if the mother is treated with ONC201
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with EGF816 and gefitinib
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapy
Breastfeeding should be discontinued if the mother is treated with nivolumab
Breastfeeding must be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with fostamatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with DAC-THU
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with trametinib
Breastfeeding should be discontinued if the mother wishes to participate in this study
Pregnant women, or women who intend to become pregnant during the study, are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD8186; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IORT
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Breastfeeding should be discontinued if the mother is treated with E6 TCR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either of those agents; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SGI-110
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either dabrafenib, trametinib, or the combination of dabrafenib and trametinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lamivudine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with anetumab ravtansine or MK-3475 (pembrolizumab)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled in the trial
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated on this study
Female participants pregnant or breast-feeding; breastfeeding should be discontinued if the mother is treated with the study drugs
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CDX-1127 (varlilumab) or nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SBRT
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184 and nivolumab
Pregnancy and breastfeeding: pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with hydroxychloroquine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with everolimus and fosbretabulin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IL-2
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cisplatin or radiation on this trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with isatuximab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with intraperitoneal interferons
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Pregnant and/or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab, dabrafenib, and trametinib
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with durvalumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral THU-Dec
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LMB-100
Breastfeeding should be discontinued if the mother is treated with LMB-100; these potential risks may also apply to other agents used in this study
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cesium 131
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated lenvatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CRLX101 and/or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IRX5183
Pregnant women are excluded from this study; breastfeeding should be discontinued if the\r\nmother is treated with ramucirumab; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib and not resumed until at least 2 weeks after the final dose
Breastfeeding should be discontinued if the mother is treated with pomalidomide; these potential risks may also apply to other agents used in this study
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with mebendazole
Subject is pregnant or nursing; breastfeeding should be discontinued if the mother is treated with ACY-1215
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with methoxyamine
Pregnant or nursing females are to be excluded; breastfeeding should be discontinued if the mother is treated with taladegib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib; this may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI-570
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with chemotherapy and/or radiation
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is treated with 8-chloro-adenosine
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with temozolomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with indium In 111 (111In-) and 90Y-basiliximab-DOTA
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-aflibercept
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the mother being treated with the study drugs
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Must not be pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated azacitidine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) while on treatment and for at least 3 months thereafter; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cisplatin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapy
A nursing mother unwilling to discontinue breastfeeding; breastfeeding should be discontinued if the mother is treated with durvalumab, tremelimumab and radiation
Pregnant women are excluded from this study. Breastfeeding should be discontinued if the mother is treated with cenersen
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CPI-613
Pregnant or planning pregnancy within the next 6 months, or breastfeeding; breastfeeding should be discontinued if the mother is treated with 5-fluorouracil
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenvatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women or women who expect to conceive a child are excluded from the study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX970); these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 232 through 1 week after receiving the last dose of study drug
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with high dose nelfinavir
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or AT13387
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 232; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BAL101553
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Mylotarg
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with navitoclax and vistusertib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or cediranib
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother participates in this trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agents
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabine
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with sirolimus
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Pregnant women are excluded from ECP; breastfeeding should be discontinued if the mother is treated with methoxsalen; pregnancy will be evaluated prior to the initiation of ECP
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Breastfeeding should be discontinued if the mother is treated with indenoisoquinolines
Pregnancy or nursing or unwilling to take adequate birth control during therapy \r\n* NOTE: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CDX-1401 or CDX-301 and poly-ICLC
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALT-803
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with 5-FU/capecitabine; pregnancy testing will be completed on all female participants of child-bearing potential by urine analysis
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD6244
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TPI 287
Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with MLN0128
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with HDACI and radiation; women of childbearing age and men sexually active with woman of childbearing age must agree to an acceptable method of birth control (double barrier) while on study
Patient is pregnant or breast feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is participating in this study
Pregnancy, nursing, or unwilling to take adequate birth control during therapy\r\n* NOTE: pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with INCB024360 and MELITAC 12.1
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237 and/or romidepsin
Breastfeeding should be discontinued if the mother is treated with PF-04449913
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostat
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with erlotinib or dasatinib
Pregnant/nursing women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oxaliplatin or mitomycin C
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IL-12; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Female participants pregnant or breast-feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide; these potential risks may also apply to other agents used in this study; lactating females must agree not to breast feed while taking lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with afatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and necitumumab
Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with AZD1775 and cisplatin; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with proton radiotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with hydroxychloroquine
Pregnant or lactating women are excluded; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 232
Pregnant and nursing women; breastfeeding should be discontinued if the mother is treated with combination ETBX-011, ETBX-051, ETBX-061
Pregnant women are excluded from this study; breastfeeding should be discontinued while the mother is receiving protocol therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and/or bevacizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2014
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this research protocol
Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pIL-12 EP + pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib; potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8327
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with eribulin and gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPI-145
Pregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening; breastfeeding should be discontinued if the mother is treated on this study with idelalisib and ofatumumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents and/or radiation
Subjects who are pregnant or breast-feeding; breastfeeding should be discontinued if the mother is treated with curcumin
Pregnant or breastfeeding women are excluded from this study; breastfeeding must be discontinued if the mother is treated with sunitinib
PHASE I: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib; potential risks may also apply to other agents used in this study
PHASE II: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pomalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with trametinib monotherapy or trametinib in combination with GSK2141795
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GSK1120212 and GSK2141795
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with neratinib and/or fulvestrant
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab; these potential risks may also apply to other agents used in this study
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with mebendazole
Pregnant women are excluded; breastfeeding should be discontinued prior to participation of the mother on study
Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with AMG 386
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CRLX101
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinib
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with vorinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated sorafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on either arm of the trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with neratinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sonidegib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this clinical trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with eltrombopag
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and eribulin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with entinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2171
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with E7389
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ganetespib; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Lactating or pregnant; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant or nursing; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study therapy\r\n* Note: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775/belinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-1775
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with paclitaxel
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated in this protocol
Breastfeeding should be discontinued if the mother is treated with sEphB4-HSA
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MPDL3280A
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with terameprocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib and onalespib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with belinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-2206 and/or dinaciclib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CUDC-907; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib R-ICE
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MVA-brachyury-TRICOM; these potential risks may also apply to other agents used in this study
Pregnancy or lactation; breastfeeding should be discontinued if the mother is treated with this regimen
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-2206
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pioglitazone
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775 (MK-1775)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Patients who are nursing infants: breastfeeding should be discontinued if the mother is treated with the study agents
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with DMS612
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with capecitabine or temozolomide or veliparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BMN 673 or AT13387
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ivabradine
Female subjects who are pregnant, have a positive serum human chorionic gonadotrophin (hCG), or are lactating and intend to breast feed a child; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NEPA
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother participates in this trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NT-I7
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with naltrexone
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab vedotin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab vedotin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Patients who are pregnant or nursing are excluded; breastfeeding should be discontinued if the mother is treated with cytotoxic chemotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with isoquercetin; these potential risks may also apply to other agents used in this study
Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with INO-8000
Women who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated\r\nwith simvastatin
Pregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with the vaccine
Women who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with simvastatin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this vaccine
Women who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with aspirin
Pregnant or breast feeding; Note: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Meriva
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with aspirin
Women must not be pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with iloprost
Women who are pregnant or breastfeeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pravastatin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with berberine; women are considered to be of child-bearing potential if they are not surgically sterile or under the age 65 and have menstruated within the last two years
Pregnant, breast-feeding, or women of childbearing potential unwilling to use a reliable contraceptive method; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with naproxen
Participants who are pregnant or breast feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Polyphenon E
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with aspirin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this drug
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 and SCH727965
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiopharmaceutical agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with 64Cu-M5A
Women who are pregnant or may become pregnant, as well as those women who are breastfeeding, will be excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother has been exposed to L-[methyl-11C]methionine; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SL-401 and azacitidine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with APR-246
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2014
Pregnant or lactating women; breastfeeding should be discontinued if the mother receives 18F-FdCyd
Pregnant or lactating women: pregnant women are excluded from this study; breastfeeding should be discontinued for at least one day if the mother receives 68Ga-DOTATATE
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LB100
Pregnant women are excluded. Breastfeeding should be discontinued if the mother is treated with LUM015.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomab
Pregnant women are excluded from this study; breastfeeding should be discontinued
Patients who are pregnant or breastfeeding are excluded from the study
Not pregnant or nursing, with negative serum pregnancy test; pregnant women are excluded from this study; breastfeeding should be discontinued; timeline: within 3 weeks prior to enrollment
Pregnant women are excluded from this study; breastfeeding must be discontinued
Pregnant or breastfeeding women will be excluded from participation in this trial
Patients may not be pregnant or nursing; pregnant women are excluded from this study; a negative pregnancy test must be documented 7 days or less prior to registration; breastfeeding must be discontinued prior to registration for this clinical trial
Pregnant women and women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Women must not be pregnant or breastfeeding; pregnant women are excluded from this study
Pregnant women and women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women or lactating women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded; breastfeeding should be discontinued
Patients who are pregnant or breastfeeding will be excluded from the study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Women must not be pregnant or breastfeeding; pregnant women are excluded from this study
Pregnant women are excluded; breastfeeding should be discontinued
Pregnant and breastfeeding women are excluded.
Pregnant or breastfeeding women are excluded from this study
Women who are pregnant or breastfeeding are excluded from the study
Pregnant women are excluded; breastfeeding should be discontinued prior to study entry
Pregnant women are excluded from this study; breastfeeding should be discontinued
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nPregnant and breastfeeding women are excluded from this study
Pregnant or breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued for the duration of active study therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding women are excluded from this study
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should also be avoided
Pregnant women are excluded from this study; breastfeeding should be discontinued while on study; patients who become pregnant while on study will be removed from the study once the pregnancy is confirmed
Pregnant and breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should also be avoided
Patients who are pregnant or breastfeeding are excluded from the study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
Pregnant women are excluded; breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug
Pregnant or nursing (lactating) women; NOTE: Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should also be avoided
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with dabrafenib/trametinib
Pregnant or lactating women are excluded from this study; breastfeeding must be discontinued for eligibility
Women must not be pregnant or breastfeeding; pregnant women are excluded from this study
Pregnant and breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to beginning treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded; breastfeeding should be discontinued prior to entry onto the study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding women; women desiring to become pregnant within the timeframe of the study are also excluded.
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to starting study treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued upon start of protocol therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if patient wishes to participate in study
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to entry onto the study
Pregnant women or women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding is not allowed during study treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to entry onto the study
Pregnant women are excluded from this study; breastfeeding should be discontinued at least two weeks prior to the start of PF-00299804 dosing
Pregnant women and women who are breastfeeding are excluded from this study
Pregnancy or breastfeeding; a pregnancy test must be performed within 7 days prior to ibrutinib initiation in women of childbearing potential; pregnant women are excluded; breastfeeding must be discontinued
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued
Pregnant or nursing women; breastfeeding must be discontinued prior to treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study and women who become pregnant while on study must be immediately discontinued; women who are breastfeeding will not be eligible for study participation
Pregnant women (admittedly, an unlikely event) are excluded from this study; breastfeeding should be discontinued
Pregnant and breastfeeding women are excluded from this study
Pregnant and breastfeeding women are not eligible for thyroidectomy and so are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or intention to get pregnant, or breastfeeding; pregnant women are excluded from this study; women who are breastfeeding will be excluded
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding mothers are also excluded from this study
Pregnant and breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with ALA
Pregnant women and women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding must be discontinued.
Pregnancy and/or nursing females
Pregnancy or active nursing of an infant is not permitted
DONOR: Pregnancy or nursing
Pregnancy or nursing patients will be excluded from the study
Pregnancy or nursing
Pregnancy or nursing
Pregnancy or nursing Mother
Pregnancy or nursing
Pregnancy as determined by pregnancy test or nursing;
Pregnancy or nursing
Known pregnancy or nursing
Pregnancy or nursing women
Pregnancy or nursing patients
Pregnancy or active nursing of an infant
